New York, Feb 10, 2026, 05:21 EST — Premarket
- Shares of Quince Therapeutics dropped about 6.6% before the market opened.
- The company has brought in LifeSci Capital to lead a strategic review and look into possible liability restructuring moves.
- The late-January Phase 3 stumble knocked the stock all the way down to penny-stock territory.
Quince Therapeutics, Inc. dropped 6.6% to about $0.13 in premarket trading Tuesday. The biotech’s shares have been volatile lately, reacting to a string of company updates and regulatory decisions.
Quince has brought on LifeSci Capital as its sole financial advisor, the company said Monday, tasking the firm with reviewing strategic alternatives and helping navigate a potential debt restructuring. Options under discussion? Partnerships, joint ventures, M&A, licensing—maybe something else entirely, per the company’s statement. Quince added it won’t provide further updates unless the board formally approves a specific action.
That question is looming now as Quince scrambles. With its lead program faltering, investor focus has veered sharply from recent clinical wins to the possibility of a deal, asset sale, or any balance-sheet play that could preserve what’s left for shareholders.
The company’s Phase 3 NEAT trial for eDSP in ataxia-telangiectasia came up short in late January, missing both its primary endpoint and a key secondary outcome. That news prompted the firm to pull the plug on clinical development, citing a need to preserve cash and “explore available options.” Chief Executive Dirk Thye, at the time, offered “tremendous gratitude” to the patients and study sites involved in the effort. SEC
As of Jan. 30, five directors resigned, a subsequent filing shows. The company insisted their departures weren’t linked to disagreements over operations, policies, or practices.
Quince stock hasn’t managed to clear the $1 mark, leaving it in violation of Nasdaq’s minimum bid-price requirements. Once the shares close below that level for 30 consecutive business days, Nasdaq puts the company on the clock, handing down a set of deadlines to remedy the deficiency. Full details at .
Still, a strategic review doesn’t always end in a transaction. The final outcome of the liability restructuring could leave common shareholders with scant, if any, value—regardless of whether they’re forced out.
Investors are waiting to see if the board takes action tied to the LifeSci mandate. The earnings report lands March 3. That release should offer a clearer read on liquidity and possible next steps.
